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1. Introduction 
Preservation of the integrity of the DNA, carrier of heritage information, is crucial for cell 
survival. Altered genetic information could lead to major perturbations in cell organization, 
function and proliferation of cancer cells. Because cancer cells are highly proliferative with 
high number of replication, DNA was the first clinically used anti-cancer therapeutic target 
with the drugs directly (intercalators/alkylating drugs) or indirectly (micro-tubules, 
topoisomerases inhibitors, modifiers of histone acetylation...) targeting DNA. Despite the 
actual development of targeted chemotherapies (against membrane receptors, kinases, the 
proteasome,…), direct DNA targeting drugs still represent a major part of the actual anti-
cancer pharmacopeia in terms of total prescriptions and efficacy. Compounds mainly bind 
DNA in three different ways: non-covalent (fitting in major or minor grooves), intercalation 
between two successive base pairs, or covalent bonding to a base, and generally lead to a 
stabilization of the DNA double helix. Only a few number from intercalating and alkylating 
families destabilizes the DNA helix. Cytotoxic effects of alkylating agents (used/developed 
for chemotherapy or from carcinogens) are strongly attenuated by the cellular DNA repair 
processes. Optimal use of DNA alkylating drugs in therapy requires a clear understanding 
of their DNA repair processes. Similarly, knowing how cells cope with the carcinogens-
induced DNA damages is of major interest regarding health in our actual society, so prompt 
to use chemical compounds insufficiently studied for long term toxicities and sometimes 
eventually identified as carcinogens (food and industries). DNA repair processes infer with 
both those Yin and Yang aspects of alkylating compounds using different machineries: base 
excision repair (BER); nucleotide excision repair (NER: long/short-patch, transcription-
coupled/global genome); mismatch repair (MMR); homologous recombination (HR) or non-
homologous end-joining (NHEJ). Fanconi anemia (FA) repair acts as a coordinator of those 
repair pathways (Moldovan & D'Andrea, 2009). Since there are yet various complete 
reviews on DNA repair processes in the literature, the present review will focus on the 
repair process of DNA destabilizing compounds.  
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2. DNA destabilizing compounds 
Stability of DNA double helix is mainly due to reversible non-covalent hydrogen bonds 
between Watson-Crick base-pairs. Local or global denaturation (melting or breathing) of the 
double-stranded DNA (dsDNA) helix is dispensable for different cellular processes: DNA 
replication, transcription and repair (Choi et al., 2004; Schneider et al., 2001). DNA melting is 
affected by sequence (AT- or GC-rich portions, some successive base pairs arrangements) 
and their specific tilt, roll, twist effects (Benham, 1996; Dornberger et al., 1999; Krueger et al., 
2006), the formation of local hairpins, 3D structures at terminal regions of the DNA helix 
(Putnam et al., 1981) or internal portions of B- to Z-DNA transition (Harvey, 1983). Such 
locally opened sites are good substrates for, or are generated by, some cellular proteins: 
DNA helicases (Betterton & Julicher, 2005), single strand binding proteins (SSBP) such as 
replication protein A (RPA) (Wold, 1997), UP1 and myeloma helix-destabilizing protein 
(Herrick & Alberts, 1976; Planck & Wilson, 1980), GAPDH-related protein P8 (Karpel & 
Burchard, 1981), High Mobility Group (HMG) proteins (Butler et al., 1985), c-Abl kinase 
(David-Cordonnier et al., 1998, 1999), HIV-1 nucleocapsid protein (Narayanan et al., 2006), 
prion protein (Bera et al., 2007), NF-B transcription factor (Mura & McCammon, 2008) and 
UHRF-1 protein (Arita et al., 2008). Besides large DNA opening, small modifications such as 
base flipping locally perturb DNA stability (Hornby & Ford, 1998) during mismatches or 
repair proteins interaction from NER (Cao et al., 2004), BER (Bellamy et al., 2007; Tubbs et 
al., 2007) or DNA methylases/demethylases (Sundheim et al., 2008).  
Besides naturally occurring DNA breathing, unzipping is induced by clinically used or 
potential anti-tumor compounds. The vast majority of DNA-interacting compounds 
stabilize the DNA double helix; only a very few of them displays the pecular ability to 
destabilize DNA helix. In this latter group, most belong to DNA intercalating or alkylating 
families.  
2.1 DNA intercalators as helix destabilizing agents 
2.1.1 Mono-intercalators 
Historically, the first DNA intercalating compound evidencing DNA destabilization 
properties was acridine orange (Figure 1), a well-known dsDNA intercalating compound 
and a strong single-stranded DNA (ssDNA) binder. It emitted green fluorescence emission 
from dsDNA binding and red luminescence from ssDNA interaction. Acridine orange 
enhances the global helix stability but exerts local denaturation of DNA (Kapuscinski & 
Darzynkiewicz, 1983; 1984; Darzynkiewicz et al, 1983). Ellipticine and adriamycin (Figure 1) 
also induce local unzipping of the DNA and bind ssDNA (Zunino et al., 1972), in contrast 
with ethidium bromide (BET), highly specific to dsDNA and stabilizing DNA. Intercalation 
of acridine orange, ellipticine and adriamycin progressively unzip the DNA helix 
preferentially in heterochromatin, ribosomes and polysomes (Darzynkiewicz et al., 1983). 
2.1.2 Bis-intercalators 
Bisacridine A (BisA) (Figure 1) is a DNA unwinding bis-intercalator deriving from acridine 
orange by cyclization of two acridine planar chromophores using polyammonium bridges. 
Initially designed to interact with ss- rather than ds-DNA (Teulade-Fichou et al., 1995), 
BisA shifts duplexes DNA toward hairpins and destabilizes dsDNA (Slama-Schwok et al., 
1997). 
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Fig. 1. DNA intercalators that destabilize the DNA helix: structures and 3D orientation of 
morpholino-doxorubicin (Top, [mmdbId:52942]) or ellipticine (Bottom, [mmdbId:52189]). 
2.2 DNA alkylators as helix destabilizing agents 
Some DNA alkylating drugs could also locally destabilize DNA double helix. Some of those 
are used/developed as anticancer drugs such as cisplatin and metal-derivatives, or more 
recently the benzoacronycine derivative S23906-1. They contrast with most DNA alkylating 
agents used or not in chemotherapy that stabilize DNA helix (for instance mitomycin C, 
dinuclear platinum, nitrogen mustards or ecteinascidine 743) (Basu et al., 1993; David-
Cordonnier et al., 2005; Fridman et al., 2003; Kasparkova et al., 1999). Electrophilic alkylating 
drugs react at nucleophilic positions of G-C or A-T bp with preferential targets: N7 position 
of dG or dA and O6 position of dG in the major groove, N3 positions of dG or dA and 
exocyclic NH2 group on C2 of dG (also called N2) in the minor groove (Figure 2). 
 
 
Fig. 2. Position of the reactive sites of some DNA alkylators on G-C or A-T base pairs. 
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2.2.1 Cisplatin and other transition-metal antitumor agents as DNA destabilizing 
drugs 
Fortuitously discovered in 1965, cisplatin (or cis-diaminedichloridoplatinum(II) is used in 
clinic since 1978 and is still frequently administrated in combinatory chemotherapies as one 
of the most effective anticancer drugs against solid tumors (Figure 3). Cisplatin forms inter- 
and intra-strand crosslinks as well as monovalent adducts. Those lesions occur primarily 
though covalent bonding to the N7 atom of guanines. The most common lesions are intra-
strand crosslink at the 5’-GG (65%) or 5’-AG (25%) dinucleotides and inter-strand 
crosslinks (5-8%). This latter lesion is more frequent using transplatin (12%), trans-
PtCl2(NH3)(quinoline) and trans-PtCl2(NH3)(thiazole) derivatives (up to 30%) (Figure 3). 
Cisplatin-induced intra-strand crosslinks at GpG base-pairs result in a strong DNA helix 
bending toward the major groove with an angle of 55-78° associated with DNA distortion, 
resulting in a destabilization of the Watson-Crick base pairing and local denaturation of the 
DNA helix (bending at 45° and unwinding by 79+/-4°) (Bellon, 1991; Malinge et al., 1994; 
Todd & Lippard, 2010). In platinated-GpG intra-strand crosslinks, the distortion varies and 
depends on the sequence context, with up to a 7 bp distortion for 1,3-intrastrand crosslinks 
within a TGTGT sequence (Kasparkova et al., 2008a). Such destabilization was found to be 
enthalpic, but not entropic, in origin. Similarly, when occurring at 5’-TGGT site, cisplatin 
adducts decrease the melting temperature of the DNA by more than 10°C which is much 
higher than that induced on 5’-CGGT and 5’-AGGC sequences (~6°C) (Malina et al., 2007). 
Such effects are not observed with transplatin which does not change the transition entropy 
or enthalpy and, consequently, does not destabilize the DNA helix (Kasparkova et al., 
2008a). Third-generation platinum antitumor derivative oxaliplatin (Figure 3) induces 
greater DNA bending, unwinding and helix destabilization than cisplatin, whereas JM118 
(Figure 3) induces DNA destabilization profiles similar to that of cisplatin (Kostrhunova et 
al., 2010). JM118 is the major metabolite of satraplatin (JM216), the first orally administered 
platinum drug that also evidenced promising therapeutic activities in prostate cancer. JM118 
induces a DNA bending with an angle of 28° toward the major groove, an angle smaller 
than that obtained with cisplatin for the same sequence (34°) (Kostrhunova et al., 2010). 
Besides the nature of the platinated drug, the surrounding DNA sequence is also of major 
importance for helix stability. Indeed, monofunctional platinum adducts at 5’-TGC triplet 
induces major DNA destabilization (Brabec et al., 1992) but none at 5’-AGT or 5’-TGA triplet 
(Schwartz et al., 1989). DNA is not the unique nucleic acid destabilized by platinated 
derivatives as evidenced using cis-[PtCl(NH3)2(OH2)]+, cis-[PtCl(NH3)(c-C6H11NH2)(OH2)]+ 
and trans-[PtCl(NH3)(quinoline)(OH2)]+ (Figure 3) which not only destabilize ds-DNA but 
also ds-RNA (Tm of -11°C and -5°C, respectively) (Hägerlöf et al., 2006).  
Besides platinum derivatives, ruthenium compounds were developed as anti-cancer drugs. 
NAMI-A was the first ruthenium derivative that entered phase I clinical trials in 1999 as an 
anti-metastatic drug (Bergamo et al., 2002), followed by KP1019 (FFC14A) in 2003 (Hartinger 
et al., 2008). Two gallium compounds, gallium maltolate and KP46 (FFC11), also entered 
phase I clinical trials in 2003 (Lum et al., 2003). As for cisplatin, ruthenium derivatives 
evidenced DNA destabilization properties. This is particularly well described for Ru-CYM 
([(6--cymene)Ru(II)(en)-(Cl)]+ and Ru-BIP, Ru-DHA or Ru-THA as biphenyl, 
dihydroanthracene or tetrahydroanthracene derivatives, respectively (Figure 3). Such 
organometallic ruthenium(II) arene complexes were rationally designed for chemotherapy 
with the idea that changing platinum for ruthenium would provide additional coordination 
sites in the octahedral complexes to modify the oxidation rate and change ligand affinity 
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and binding kinetics (C.X. Zhang & Lippard, 2003). From this series, Ru-CYM presents the 
highest DNA helix destabilization activity, together with the smaller unwinding angle in 
supercoiled plasmid DNA (7° vs. 14° for Ru-BIP, Ru-DHA and Ru-THA), in correlation with 
its lack of intercalation and the formation of monoadducts at N7-dG (Nováková et al., 2009). 
New Ru-derivatives monodentate-Ru(II) and [Ru(terpy)(4,4'-(COLysCONH2)2bpy)Cl]3+ also 
destabilize DNA (Nováková et al., 2010; Triantafillidi et al., 2011). For gallium-complexed 
compounds, interaction of trivalent Ga-cations with calf-thymus DNA resulted in major 
helix destabilization with perturbations at A-T base pairs sites (R. Ahmad et al. 1996).  
 
 
Fig. 3. Structure of cisplatin and other transition-metal agents as DNA destabilizing drugs 
and 3D orientation [mmdbId:47796] (cisplatin) and [mmdbId:69361] (oxaliplatin). 
2.2.2 Carcinogens as DNA destabilizing agents 
DNA interaction of carcinogen, adduct formation and their repair processes are widely 
studied using carcinogens from environmental and tobacco smoke. Some of them have the 
ability to destabilize the DNA helix: BPDE ((+/-)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-
epoxide) and 4-OHEN (4-hydroxyequilenin-O-quinone) (Figure 4). 
The smoke carcinogen benzo[a]pyrene (BaP) is metabolized into several enantiomers of 
BPDE that covalently bond the exocyclic NH2 group of guanines to form a bulky adduct in 
the minor groove of the DNA helix, resulting in its destabilization (Zou & Van Houten, 
1999). Due to the orientation of the reactive epoxide group on asymmetric carbons, several 
enantiomers are produced. The most carcinogenic is 10S(+)-trans-anti-BPDE N2-dG adduct 
followed by the stereo-isomeric 10R(+)-cis-anti-BPDE-N2-dG adducts. Covalent bonding to 
DNA is associated with base-displaced intercalation where the bulky adduct prevents the 
hydrogen bonding of the amino group of guanine with the opposite cytosine. This results in 
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a base-flipping where the (+)-anti-B[a]P-N2-dG bulky adduct is located in the minor groove 
and the opposite cytosine is positioned in the major groove (Cosman et al., 1993). The 
precise orientation of this highly carcinogenic 10S(+)-trans-anti-B[a]P-N2-dG adduct depends 
on the sequence surrounding the target guanine (Cai et al., 2010). DNA is untwisted at 5’-
CGG*C sites where a large bend is induced in the DNA helix, but not at 5’-CG*GC 
sequences where, conversely, DNA helix is destabilized in its portion orientated 5’ to the 
lesion (Rodríguez et al., 2007). Such differences result in different protein/DNA recognition 
and repair activities (see 3.4). Thermal destabilization was also observed using 14R(+)-trans-
anti-DB[a,l]P-N2-dG adduct (Zheng et al., 2010) or 14S(-)-trans-anti-DB[a,l]P-N6-dA adducts 
whereas 14R(+) isomer stabilizes the ds-DNA (Cai et al., 2011). 
 
 
Fig. 4. 3D orientation of (+)-anti-BPDE [mmdbId:52106] and the psoralen derivative HMT 
[mmdbId:52343] and structure of some DNA alkylators that destabilize the DNA helix.  
The hormone-derived genotoxic compound, 4-OHEN, derives from equilin and equilenin, 
two equine oestrogens present in hormone substitution therapies used to prevent the 
uncomfortable effects of menopauses but are also thought to increase breast cancer 
incidence in the population of hormonally-treated women (Rossouw et al., 2002). Its ortho-
quinone form is cytotoxic and genotoxic (Pisha et al., 2001) through the formation of bulky 
DNA lesions at dA, dC and dG (but not at T residues) (Kolbanovskiy et al., 2005) which 
were detected in both cell culture and breast cancer biopsies from patients treated with 
hormone substitution therapies (Embrechts et al., 2003). 4-OHEN derived from the 
intermediate catechol 4-hydroxyequilenin which was generated from a rapid conversion of 
both equilin and equilenin in the organism to four stereo-isomers differently affecting the 
3D-structure of the DNA helix (Ding et al., 2007). For adducts on cytosine, the syn- or anti-
conformations of the bulky rings of 4-OHEN point along the major or the minor groove 
(Ding et al., 2005). Interestingly, alkylation at dA or dC residues is associated with a strong 
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decrease in the melting temperature (Tm) of a 11-bp oligonucleotide, with the magnitude of 
the negative Tm values being lower when the adduct is located at 1 or 2-bp from the end of 
the 11-bp DNA (-6 to -9°C) then when it is located in its medium part (positions 4 to 8) with up 
to a -21 to -27°C decrease of Tm. Similarly, the stereoisomeric orientation of the 4-OHEN 
adduct affects the base-stacking, groove sizes and subsequent distortions and is also crucial for 
the extent of DNA destabilization (Kolbanovskiy et al., 2005). 
2.2.3 Psoralen derivatives 
Psoralen is a chemotherapeutic agent known to cause DNA inter-strand crosslinks (ICLs) 
upon absorption of two photons from UVA irradiation at 365 nm, preferentially at 5′-TA and 
to a lesser extend at 5′-AT dinucleotides. This activity was the basis for use of psoralen and 
UVA exposure (PUVA therapy) to treat cutaneous diseases like psoriasis, vitiligo, atopic 
dermatitis or cutaneous T cell lymphomas. However, such treatment increased the risk of 
squamous and basal cell carcinomas (Teicher, 1996). Psoralen-induced ICLs are classically 
used models for DNA repair of ICLs. The psoralen derivative 4'-(hydroxymethyl)-4,5',8-
trimethylpsoralen (HMT) (Figure 4) evidenced DNA destabilization by mono-addition of a 
psoralen residue to both thymines (one on each strand) of 5’-GGGTACCC sequence.  
2.2.4 Benzo-acronycine derivatives 
Acronycine is a natural alkaloid extracted from the bark of an Australian ash scrub that 
presented interesting antitumor activities but was poorly soluble and, consequently, too 
toxic in first clinical trials. The discovery of an unstable acronycine epoxide opened the way 
to the rational drug design of S23906-1 (Figure 4), that appeared to be a highly active 
compound (Guilbaud et al., 2001) with an original mode of action (David-Cordonnier 2002; 
2005; Depauw et al., 2009) and consequently entered phase I clinical trials in 2006. As for the 
clinically used drug Ecteinascidine 743 (ET-743, Trabectedin, Yondelis TM from Pharmamar), 
S23906-1 alkylates the exocyclic NH2 group of guanines in the minor groove. But, in contrast 
with ET-743, S23906-1 does not reinforce the stability of the ds-DNA helix but destabilizes it, 
generating portions of ss-DNA (David-Cordonnier et al., 2005; Depauw et al., 2009). Various 
spectral and biochemical approaches convinced with this conclusion. Indeed, classical DNA 
melting temperature studies evidenced a strong decrease of the Tm values upon alkylation 
with S23906-1 or other biologically active benzo-acronycine derivatives. Similarly, spectral 
analysis of the ratio of fluorescence properties of picogreen (a ds- and ss-DNA interacting 
dye) and BET (a ds-DNA specific dye) evidenced an increase of picogreen vs. BET 
fluorescence which enlightens the generation of single-stranded portions of the DNA upon 
S23906-1 alkylation. Biochemical approaches like digestion of the alkylated DNA by single-
strand specific nuclease S1 and electrophoretic mobility shift assays (EMSAs) confirmed the 
opening of the DNA. The destabilization was relatively wide since mapping with nuclease 
S1 evidenced locally opened DNA portions within a 117 bp DNA fragment alkylated by 
S23906-1 whereas EMSAs, performed with oligonucleotides as long as 24 bp, evidenced 
fully single-stranded alkylated oligonucleotides in the presence of S23906-1 or derivatives 
(David-Cordonnier et al., 2005; Depauw et al., 2009). 
3. Repair processes for DNA destabilizing lesions 
DNA adducts are critical lesions for cell proliferation and survival. Single or multiple DNA 
repair machineries could be implicated in the removal of these damages, as for example 
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BER, GG-NER (global genome) or TC-NER (transcription-coupled), MMR, HR or NHEJ. 
Only few data are published about the consequences of non-covalent DNA destabilizing 
agents on protein/DNA binding from the repair machineries. These data on BisA function 
reported that insertion of BisA could flip the mispaired thymine to an extrahelical base 
subsequently inducing a sterical blockage of DNA glycosylases binding (David, 2003). The 
present section will therefore focus on alkylating compounds. As examples, we will shortly 
present the repair processes for the well-studied temolozomide-induced lesions in the major 
groove and for the DNA stabilizing drug ET-743, as an original minor groove alkylating 
agents that “poison” the NER machinery to exert its anti-tumor properties, before 
presenting the current knowledge on DNA repair of DNA destabilizing lesions. 
3.1 Repair of temolozomide-induced DNA lesions 
Temolozomide (TMZ, Temodar®, Figure 5) is a monofunctional alkylating agent chemically 
related to dacarbazine. It is active in vitro and in vivo against a wide variety of tumor type 
and particularly efficient in malignant glioma (Newlands et al., 1997). Contrasting with 
dacarbazine, TMZ does not require to be activated by enzymatic oxidation, but 
spontaneously hydrolyses to 5-(3-methyltriazen-l-yl)-imidazole-4-carboximide (MITC) at 
pH above 7. MITC is then broken down to (i) the reactive methyldiazonium cation which 
next loses the methyl group in the presence of DNA or proteins and (ii) the inactive 5-
aminoimidazole-4-carboxyamide moiety (AIC) (1). TMZ treatment leads to different adducts 
on the double helix DNA: N3-methyladenine, N7-methylguanine and O6-methylguanine  
 
 
Fig. 5. DNA repair pathways for TMZ-induced damage. 
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(Newlands et al., 1997) and cell sensitivity to TMZ treatment depends on multiple DNA 
repair mechanisms (2). The major one is the recognition of methyl lesions from O6 position 
of guanines by the O6-methylguanine DNA methyltransferase (MGMT) protein which 
directly converts the methylated DNA to its normal, undamaged state (3). MGMT enzymatic 
activity is crucial for TMZ resistance in vivo suggesting that MGMT expression may predict 
the response of patients to TMZ treatment (Everhard et al., 2006; McCormack et al., 2009). 
However, other repair mechanisms are also implicated since some cell lines with low 
MGMT expression still evidence significant resistance to TMZ (Fukushima et al., 2009).  
When O6-methyguanine is not repaired by MGMT, it may lead to an O6-
methylguanine:thymine mismatch during DNA replication. The following DNA replication 
cycle can then pair thymine with adenine in place of the original guanine, thus leading to 
transition mutations (4). However, the cytotoxic property of TMZ is mostly linked to MMR 
pathway through O6-methylguanine:thymine mismatch recognition and repair by this 
system (5). MMR is not involved in TMZ chemo-resistance but in TMZ cytotoxicity, 
associated with cell cycle blockade at G2 checkpoint (Caporali et al., 2004), activation of p53 
and ATM, leading to cell death (6). The MRN (Mre11/Rad50/Nbs1) complex was evidenced 
as the earliest sensor of TMZ-induced damage (Mirzoeva et al., 2006). It undergoes a series 
of conformational changes that activates the protein sensor ATM (ataxia telangiectasia 
mutated) which, subsequently, activates Chk1 and Chk2 to block cell cycle. TMZ induces 
p53-mediated apoptosis in MMR-proficient but not in MMR-deficient cells (D’Atri et al., 
1998). Thus, deficient MMR is another mechanism for resistance to TMZ (Cahill et al., 2007).  
Besides MGMT and MMR, BER is also implicated in TMZ lesion repair. More than 80% of 
N7-methylated purines are recognized and excised by the BER enzyme N-methylpurine 
DNA glycosylase (MPG) (Trivedi et al., 2008; J. Zhang et al., 2010) (7). As a consequence, 
disruption of BER system sensitizes MMR-deficient and proficient cells (Liu et al., 1999). The 
major MPG-dependent repair occurs via short-patch BER, a mechanism whereby only the 
damaged nucleotide is excised. So, BER pathway is another contributor of cell resistance to 
TMZ and its efficacy depends on specific BER gene expression and activity (Fishel et al., 
2008). DNApol β or MPG-deficient cells are more sensitive than wild-type cells to TMZ-
induced cell death, whereas MPG over-expression increases TMZ-induced cytotoxicity 
(Tang et al., 2011; Trivedi et al., 2008). Similarly, inhibition of poly(ADP-ribose) polymerase-
1 partially restored sensitivity to TMZ (J. Zhang et al., 2010). 
Both methylated DNA lesions can lead to SSBs in a DNA repair-dependent manner (BER, 
MMR). If unrepaired before replication, SSBs convert in DSBs, a more mutagenic and lethal 
lesion (Newlands et al., 1997). However, DSBs could be processed by the conservative HR 
pathway to give back undamaged double stand DNA or by NHEJ repair machinery 
potentially resulting in chromosomal rearrangements between chromatide or deleterious 
genomic rearrangements as other toxic lesions (8). Other inter-crossings between repair 
pathways are not presented in this scheme: a role of some MMR proteins in the NHEJ 
pathway to repair DSB during G1 phase of the cell cycle or in HR pathway through the 
regulation of the early G2 checkpoint and inhibition of DSB repair (Y. Zhang et al., 2009) as 
well as the implication of Fanconi anemia FANC-D1 (Kondo et al., 2011). 
3.2 DNA repair process and implication in ET-743 expressing cytotoxicity 
ET-743 is a tetrahydroisoquinoline alkaloid isolated from the tunicate Ecteinascidia turbinata 
which is approved as an orphan drug against advanced soft tissue sarcoma and, in 
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association with doxorubicine, in refractory cisplatin-sensitive ovarian cancers. This DNA 
minor groove binder (Pommier et al., 1996) bends DNA toward the major groove (Hurley & 
Zewail-Foote, 2001). ET-743 (Figure 6) is composed of three subunits: A and B are involved 
in DNA binding at specific sites (David-Cordonnier et al. 2005; García-Nieto et al., 2000; 
Pommier et al., 1996) and C protrudes out of the double helix thus facilitating the interaction 
of ET-743 with nuclear proteins such as transcription factors or DNA repair proteins (1). The 
formation of such protein/ET-743-DNA complex prevents the transcription of different 
genes (Friedman et al., 2002; Jin et al., 2000) and induces a rapid degradation of transcribing 
RNA polymerase II in TC-NER proficient, but not deficient, cells (Aune et al., 2008).  
By contrast with other DNA damaging agents, NER-deficient cell lines are resistant to ET-
743, and restoration of NER functions sensitizes cells to the drug. Indeed, the TC-NER 
complex is trapped during the repair process of ET-743-DNA damage (Damia et al., 2001; 
Takebayashi et al., 2001) through the formation of a stable XPG/DNA ‘cytotoxic complex’ 
(Herrero et al., 2006)(2). In a replication-independent manner, the MRN complex is recruited 
(3) and induces DSBs subsequently recognized by DNA-PK from the HR machinery. DNA-
PK then phosphorylates H2AX and activates ATM (Damia et al., 2001) and Chk1 to bypass 
G2/M and S phases checkpoints and promote cell death (Herrero et al., 2006).  
Protein recognition of ET-743-DNA adducts also induces the formation of DSBs through 
replication fork collapse (Soares et al., 2007; Takebayashi et al., 2001)(4), as well known for 
topoisomerase/drug/DNA poisoning complexes. Such DSBs are repaired by HR (acting 
mainly in G2-M phases) but not by NHEJ (Soares et al., 2007; Tavecchio et al., 2008)(5).  
 
 
Fig. 6. DNA repair pathways for ET-743-induced DNA damage. 
3.3 DNA repair for cisplatin and other transition-metal antitumor agents  
Regarding DNA repair, local destabilization of the double helix, base-flipping, DNA bending 
and poor base-stacking following cisplatin alkylation are determinant for recognition of DNA 
lesions by repair proteins (C.G. Yang et al., 2009; W. Yang, 2006). Several repair machineries 
are implicated in metal-drug-induced DNA adduct recognition, removal and cytotoxicity 
(Basu & Krishnamurthy, 2010; S. Ahmad, 2010). First, NER is an important actor for the 
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removal of both 5’-GG, 5’-AG and 5’-GNG cisplatin intra-strand crosslinks, with a preference 
for the latter site. The induced-kink, being greater for 5’-GNG than 5’-GG or 5’-AG alkylated 
sites, seems to be of major relevance for NER recognition (1, in Figure 7). Particularly, 
platinum adducts are recognized by the global genome-NER XPC/hHR23B “sensor complex” 
(Neher et al., 2010) and XPC expression or polymorphism predicts the response to cisplatin 
treatment in lung cancers (Lai et al., 2011; L.B. Zhu et al., 2010). Lesions induced by cisplatin, 
oxaliplatin and JM216 are similarly repaired whereas transplatin-induced lesions, which 
poorly affect 3D structure of DNA, are poorly repaired by NER.  
MMR is also important to remove platinated lesions (2). Facilitated by cisplatin-induced 
kink, MSH2 binding is associated with a 60° angle generated through intercalation of its 
Phe39 at the lesion site. MSH2/MSH6 complex (Mut-S) recognizes cisplatin crosslinks 
(Castellano-Castillo et al., 2008; Fourrier et al., 2003) but not transplatin mono-adducts from 
[Pt(dien)Cl]+. Translesion bypass is also implicated in cisplatin toxicity. Interestingly, 
oxaliplatin lesions are more bypassed by DNA polymerases than cisplatin, in relation with 
their difference in DNA bending/destabilization potencies. Mutants FANC-C and –D of 
Fanconi anemia pathway also sensitize cells to Pt-drug (Kachnic et al., 2010). 
 
 
Fig. 7. DNA repair pathways for platinated DNA. 
Of major concern, cisplatin adducts are also recognized by HMG proteins (3). Similarly to 
MutS complex recognition, the large induced bend is crucial for this recognition and fits 
perfectly with the L-shaped structure of HMG DNA binding domain (HMG-box) to reduce 
the “cost” of DNA bending for HMG-box (Privalov et al., 2009). Insertion of Phe37 between  
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the two platinated guanines in 5’GG dinucleotide stabilizes the binding but is regulated in a 
redox manner. Indeed, the formation of a disulfure bond between the thiol groups of Cys22 
and Cys44 on helix II and III, respectively, of HMG-box infers with the correct planar 
insertion of Phe37 between the two guanines at crosslink site (Park & Lippard, 2011). 
Binding of HMG-B1 (and HMG-B2) stabilizes the cisplatin-induced bent and supercoiling of 
the DNA helix, increases the sensitivity of the cells to cisplatin and shields the platinated 
adducts from repair by the human DNA excision machinery (J.C. Huang et al., 1994). As a 
consequence of the degree of kink of the DNA, HMG proteins poorly bind to oxaliplatin 
adducts which induce relatively small DNA-bending and DNA destabilization (Figure 3), 
and so poorly protects them from DNA repair (Kasparkova et al., 2008b). This difference 
correlates with the lower level of DNA lesions in oxaliplatin- versus cisplatin-treated cells. If 
HMG-B1 and –B2 binding participates in platinated-agent-induced cytotoxicity (Sharma et 
al., 2009), bent platinated-DNA is also a good substrate for transcription factors from HMG-
box family such as SRY, LEF-1 and UBF-1, resulting in the transcriptional changes observed 
in treated cells (Chvalova et al., 2008; Treiber et al., 1994; Trimmer et al., 1998). For the repair 
of other platinum derivative-induced DNA damages, JM108 evidenced higher level of 
protein/DNA cross-links such as DNA-PtII-NF-κB cross-linked complexes (4). Those lesions 
are less efficiently removed from DNA by the cell repair system (Kostrhunova et al., 2010). 
Other studies described the binding of PARP-1 protein to cisplatin adduct at 5’-GG and 5’-
GNG intra-strand crosslinks on duplex DNA with a preference for 5’-GG platinated site to 
protect it from DNA repair and thus to increase cytotoxicity (G.Y. Zhu et al., 2010), 
particularly in MSH3-deficient cells (Takahashi et al., 2011) (5). Such side effect of PARP-1 
orientates current phase I/II clinical trials using PARP inhibitors (CEP-6800, AZD2281 or 
ABT-888) as sensitizing agents in combination with cisplatin and carboplatin. A recent paper 
suggests that PARP is a pharmacological target of platinum- and other metal-based drugs 
showing PARP inhibition using Pt- (cisplatin), Ru- (RAPTA-T, NAMI-A) or Au- (Auphen, 
Aubipy) derived drugs (Mendes et al., 2011). 
In a general manner, NER process of DNA lesions induced by ruthenium-drug appears to 
be less efficient than for platinum adducts. Ru-CYM and Ru-THA destabilize the DNA helix 
via different enthalpic effects and differ in terms of their DNA base-pair intercalation 
propensities. Comparison of their DNA repair processes has been used as a model for 
understanding the link between DNA destabilization and repair. Interestingly, Ru-CYM 
adducts (that destabilize the DNA helix much more than Ru-THA adducts) are excised more 
efficiently than Ru-THA complex adducts. Such observation is in good agreement with 
lower binding of RPA helicase to Ru-THA- than to Ru-CYM- adducts (Nováková et al., 
2005). Ru-THA is also more cytotoxic than Ru-CYM, suggesting that DNA destabilization 
plays a major role in the cytotoxicity of these series of compounds. 
3.4 DNA repair for the carcinogen BaP (BPDE) and 4-OHEN adducts 
In prokaryote, the NER sensor protein UvrB recognizes BPDE/DNA adduct (1 in Figure 8). 
Lesion-induced local thermodynamic destabilization and associated nucleotide flipping 
facilitate this recognition (Jia et al., 2009) with excision efficiencies changing up to a factor of 
3 with stereoisomery (i.e. (+) vs. (-), cis- vs. trans-orientation)(Zou & Van Houten, 1999).  
By contrast, the BaP-induced lesions are recognized in eukaryotic higher cells by the NER 
machinery's “sensor” protein XPC, associated with HR23B to initiate DNA repair (2). 
Weaker recognition by XPC/HR23B complex of the (+)-trans-B[a]P-N2-dG adduct, relatively 
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to that of the other conformers, contributes to its higher mutagenic potential (Mocquet et al., 
2007). Lesion recognition by XPC requires DNA bending facilitated by local conformational 
flexibility (Clement et al., 2010) and destabilization of the base-pairing (Brown et al., 2010). 
Such recognition is driven by Trp690 and Thp733 amino-acids identified as “aromatic 
sensors” (Maillard et al., 2007). Upon treatment with BaP, human bronchial epithelial 16HBE 
cells expressed higher levels of the heat shock protein 70 and the NER proteins XPA and 
XPG, both three proteins co-localizing in the nucleus, suggesting that Hsp70 is also 
implicated in the DNA repair response to BPDE-DNA adducts (J. Yang et al., 2009). The 
highly mutagenic (+)-(7R,8S,9S,10R)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydro-
benzo[a]pyrene-DNA lesion leads to different repair processes depending on sequence 
context, associated with the destabilization potency. Indeed, for an identical BaP-DNA 
lesion leading to differently orientated bulky lesions, sequence-dependent effect was 
observed: DNA destabilized at 5’-CG*GC site is more rapidly excised in cell-free human 
HeLa extracts than DNA bent at 5’-CGG*C site (Rodríguez et al., 2007). As the DNA helix is 
readily opened upon alkylation, recognition of the lesion by repair protein (including 
induction of base flipping) is less energetic and, thus, is quicker for DNA already 
destabilized at 5’-CG*GC site than for duplex DNA bent at 5’-CGG*C site, clearly 
evidencing the importance of DNA sequence/global structure context for an efficient repair 
of BPDE-DNA adducts (Yuqin et al., 2009). Moreover, interesting data arise from 
comparison of the 3D conformation and the NER excision efficiencies for dA adducts 
formed using the bay region BPDE and the fjord region benzo[c]phenanthrene diol epoxide 
(B[c]PhDE) (M. Wu et al., 2002). The bay region of B[a]P is more extended, planar and rigid 
than the B[c]Ph fjord region, being twisted and curved. Consequently, B[a]P-dA adducts are 
associated with greater backbone distortion, unwinding, intercalation potency and  
 
 
Fig. 8. DNA repair pathways for BPDE-induced DNA damage. 
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disturbed Watson-Crick hydrogen bonding than B[c]Ph-dA adducts, in correlation with 
stronger excision efficiency by NER machinery. The fjord region B[c]Ph-dA adducts being 
poorly excised lead to more tumorigenic activities. HMG-1 and -2 proteins are also 
implicated in bulky BPDE-adducts recognition (Lanuszewska & Widlak, 2000) but the 
consequences on repair or cell death are unknown (3). HMG binding might protects adduct 
recognition by repair proteins as for platinated DNA, but this needs further evaluation.  
Excision of bulky 4-OHEN-DNA adducts by NER proteins also depends on both the nature 
of the alkylated base, its stereo-isomery and the sequence context. For instance, 4-OHEN-dC 
adducts are more efficiently excised from the DNA than the 4-OHEN-dA adducts (D. Chen 
et al., 2006). It was reported in male zebrafish that 17a-ethinylestradiol, as a source of 4-
OHEN, induces a decrease in NER activity as part of a decrease of the expression level of 
some NER genes such as XPC, XPA, XPD and XPF, but not of HR23B (Notch et al., 2007). 
3.5 DNA repair for psoralen-DNA adducts 
DNA alkylation by psoralen can lead to inter-strand crosslinks (ICL) or mono-adducts 
(MA). Psoralen-ICLs (Figure 9) are eliminated during the replication process, associated 
with HR (1), MMR (2) and error-prone translesion DNA polymerases (Dronkert & Kanaar, 
2001). NER proteins such as XPC/hHR23B complex and XPA/RPA complexes are also 
implicated in the repair of psoralen-ICL (Thoma et al., 2005) and could cooperate with MMR 
to excise the lesions (Zhao et al., 2009). By contrast, thymine-psoralen mono-adducts (3) are 
moderately excised from the DNA by the NER system (Vasquez et al., 2002), because of adduct 
recognition by HMG-B1 which recruits RPA helicase (4) (Lange et al., 2009) or by MMR  
 
 
Fig. 9. DNA repair pathways for psoralen-induced DNA damage. 
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(Q. Wu et al., 2005; 2008). Psoralen monoadducts are good substrates for 3-Methyladenine 
DNA glycosylase (MPG) (Maor-Shoshani et al., 2008) and the human oxidative DNA 
glycosylase, NEIL1, which catalyses the ,-elimination at AP site, leaving a 3’-P termini at 
the resulting SSB (5) (Couvé-Privat et al., 2007). Fanconi anemia pathway was also 
implicated in the repair process, in link with NEIL1 stability and NER efficiency (Macé-
Aimé et al., 2010). 
3.6 DNA repair for benzoacronycine-DNA adducts 
S23906-1 alkylates the DNA in the minor groove and induces a strong destabilization of the 
DNA helix. Two reactive acetate groups are positioned on asymmetric carbons leading to 
four pure enantiomers: 2 cis (1R;2R and 1S;2S) (the cis-racemate being S23906-1) and two 
trans (1R;2S and 1S;2R) isomers. Both pure enantiomers react with DNA and destabilize the 
DNA helix but at different extends. The most potent DNA destabilizing ones (1S;2S and 
1S;2R) being those presenting the most active anti-tumour activities in animal models 
(Depauw et al., 2009). Therefore, the rate of DNA destabilization is different depending on 
the orientation of the core of the adducts regarding the opened drug/DNA structure, and 
correlates with different cellular and anti-tumour effects. Such strong destabilisation could 
affect single-stranded endonuclease and DNA repair activities. There is currently only 
partial knowledge on the repair of S23906-1 DNA adducts. The NER proteins XPC and CSB 
are involved in cell sensitivity to S23906-1, associated with both global genome repair and 
transcription-coupled NER (Rocca et al., 2010). ATR coordination, RPA recognition and 
Chk1 activation were also implicated in responses to S23906-1 DNA damages (Soares et al., 
2011). Process of the lesions is associated with DSB as secondary DNA lesions important for 
cytotoxicity of S23906-1, associated with histone H2AX phosphorylation (Léonce et al., 
2006). Of major interest, the most potent destabilizing isomer of S23906-1 was evidenced to 
be also the most cytotoxic on cellular models and the most efficient on xenografted animal 
models (Depauw et al., 2009). Current ongoing research is identifying proteins implicated in 
S23906-1/DNA adduct recognition and evaluating their impact on S23906-1 cytotoxic 
activity (personal communication). Locally destabilized DNA could favour the recognition 
of DNA lesion by “DNA repair sensors” thus increasing the efficiency/kinetic of the 
removal of the DNA lesion.  
4. Conclusion  
Destabilization of the DNA helix that is induced by drugs is an important aspect of the 
antitumor mechanism of action of this series of compounds besides they represent just few 
droplets in an ocean of DNA-interacting compounds that mainly stabilize the double helix. 
As evidenced here, stabilizing vs. destabilizing compounds differs in terms of molecular and 
cellular processes: DNA repair, transcription or replication. From the different series 
(platinum, ruthenium, BPDE, benzoacronycines), the level of DNA destabilization correlates 
with the efficiency of protein recognition and anti-tumor/cytotoxic activities. Therefore, we 
believe that it is important not to consider DNA destabilization as a unique process but in 
relation with potential associated bending of the DNA helix (as evidenced using oxaliplatin- 
and cisplatin-induced distortions or the different isomers of BPDE) and with the size of the 
locally destabilized DNA (for instance, portions of DNA opened by benzoacronycines are 
strongly sensitive to single-strand-specific nucleases). The most recent and ongoing studies 
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on the importance of DNA destabilization on DNA repair processes and induced-cytotoxic 
activities illustrate the need for an accurate examination of precise mode of binding 
/bonding to DNA of potential anti-cancer drugs in terms of 3D structure/activity relation-
ships and to clearly evaluate the cellular consequences (cytotoxicity, DNA repair processes). 
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